(Address
of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (925) 223-6700
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.07.
Submission of Matters to a Vote of Security Holders
On
June 2, 2016, Natus Medical Incorporated (the “Company”) held its annual meeting of stockholders. At this meeting, James B. Hawkins and Robert A. Gunst were re-elected to serve on the Board of Directors for a three-year term until 2019. Additionally, shareholders ratified the appointment of KPMG as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016, provided advisory approval of the Company’s named executive officer compensation.
Proposal 1: Election of Directors
Nominee
For
Against
Abstain
Broker
Non-Votes
James
B. Hawkins
25,910,812
1,320,573
7,039
3,984,304
Robert A. Gunst
26,237,720
993,107
7,597
3,984,304
Proposal
2: Ratification of KPMG as Auditors
For
Against
Abstain
31,167,568
23,436
31,724
Proposal
3: Advisory Approval of the Company’s Executive Compensation
For
Against
Abstain
Broker
Non-Votes
25,569,547
1,543,030
125,847
3,984,304
No
other matters were considered or voted upon at the meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
